Kumar, Anil, Garg, Ruchika, Kumar, Puneet · Pharmacological reports : PR · 2008
This study tested whether a medication called trazodone could help mice recover from fatigue caused by repeated physical stress. Researchers found that trazodone did reduce fatigue-like behavior and improved activity levels in stressed mice. The protective effect seemed to involve a chemical messenger in the body called nitric oxide, suggesting this might be one way trazodone works to improve symptoms.
This study identifies nitric oxide signaling as a potential mechanistic target in trazodone's therapeutic action, which could explain why some ME/CFS patients respond to this medication. Understanding the biochemical pathways involved in treatment response may help researchers develop more effective therapies or identify which patients are most likely to benefit. The finding that modulating NO levels changes treatment effectiveness opens new avenues for personalized approaches to fatigue management.
This study does not prove that trazodone is effective in human ME/CFS patients, as it was conducted only in mice using an acute stress model that may not accurately reflect the complex, multi-system pathology of human disease. The study demonstrates association between NO modulation and trazodone's protective effects in this specific animal model but does not establish that this mechanism operates identically in humans. Results cannot be directly translated to clinical practice without human clinical trials.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →